It’s only fair to share… Navepegritide Cas 2413551-27-4 Molecular Formula: C₂₃₁H₃₈₆N₆₄O₆₇S₅ + (C₂H₄O)₄ₙ (approx. 45 kDa), 1804.0 g/mol MOLECULAR FORMULA C231H386N64O67S5 + (C2H4O)4nMOLECULAR WEIGHT approx. 45 kDa The structure of navepegritide (YUVIWEL®) is built using a “prodrug” design. It is not a simple small molecule, but rather a complex conjugate consisting of three distinct components designed to release the active …
Tag «APPROVALS 2026»
Milsaperidone
It’s only fair to share… Milsaperidone CAS 501373-88-2 C24H29FN2O4 MW 428.50 FDA APPROVED 2/20/2026, Bysanti, To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol 7SV1ZOG031, P-88-8991, (-)-, (S)-Hydroxy Iloperidone, P-88, VHX 869, VHX-896 Milsaperidone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name VHX-896 and …
Copper histidinate
It’s only fair to share… Copper histidinate CAS 12561-67-0 AND 13870-80-9 MF C12H16CuN6O4 FDA 2026, JAN/12/26, Zycubo, To treat Menkes disease, APPROVALS 2026, 9078K3MO9U, MN 88, CUTX 101 copper bis((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate) Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease.[1] Copper histidinate is a copper replacement therapy given by subcutaneous injection.[1][2] …
Difamilast
It’s only fair to share… Difamilast FDA 2026, APPROVALS 2026, difamilast, Adquey, 2/12/2026, To treat mild to moderate atopic dermatitis PMDA Moizerto, JAPAN APPROVED 2021/9/27 ジファミラスト ディファミラスト; 地法米司特 N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3- oxazol-4-yl}methyl)-2-ethoxybenzamide OPA-15406 Formula C23H24F2N2O5 CAS 937782-05-3 Mol weight 446.4439 MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406 Efficacy Anti-inflammatory, Phosphodiesterase IV inhibitor Comment Treatment of atopic dermatitis OriginatorOtsuka Pharmaceutical Development …